The ATF1 Knockout A-549 Polyclonal Cells constitute a human CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the ATF1 gene in the A-549 lung adenocarcinoma cell line. This polyclonal knockout product offers a genetically heterogeneous loss-of-function model for studying ATF1-dependent signaling and transcription without clonal selection artifacts. The engineered knockout provides a valuable tool for investigating the functional roles of ATF1 in cancer biology and stress-responsive gene regulation.
The A-549 cell line is a human lung adenocarcinoma epithelial model derived from a 58-year-old Caucasian male. Widely used as a model of alveolar type II pulmonary epithelium, it is a cornerstone in lung cancer research, providing a well-characterized platform for investigations into oncogenic signaling and drug responses.
ATF1 is a bZIP transcription factor that binds cAMP response elements (CRE) to regulate gene expression. It is activated by phosphorylation via PKA, ERK, and CaMK in response to cAMP, MAPK, and calcium signals. Phosphorylated ATF1 recruits coactivators CBP/p300 and CRTC family members to stimulate transcription of target genes including cyclin D1, Bcl-2, survivin, c-Fos, Mcl-1, and VEGF. Through these effectors, ATF1 integrates diverse stimuli to promote cell survival and proliferation.
In A-549 cells, ATF1 contributes to oncogenic transcriptional programs. Disruption of ATF1 in this polyclonal knockout population is expected to impair expression of pro-survival and proliferative genes, potentially sensitizing cells to apoptosis and reducing metastatic traits. This model allows evaluation of ATF1 loss in a heterogeneous cell pool, reflecting tumor heterogeneity, and is valuable for dissecting ATF1??s role in lung adenocarcinoma and identifying therapeutic vulnerabilities.
Applications include the study of cAMP/CREB-regulated transcription, drug screening against ATF1-dependent pathways, and functional analysis of proliferation, apoptosis, and invasion. Representative assays include Western blotting, RT-qPCR, RNA-seq, ChIP-qPCR, viability/apoptosis assays, migration/invasion assays, and CRE-luciferase reporters. The knockout cells are also suitable for co-immunoprecipitation of ATF1 complexes. For more information, please contact Ascent Research.
